Two Re­pub­li­can law­mak­ers feel 'oblig­ed' to warn drug­mak­ers that De­mo­c­rat col­league Cum­mings is pur­port­ed­ly out to de­flate their stock prices

The pro­lif­ic chair­man of the Com­mit­tee on Over­sight and Re­form Eli­jah Cum­mings kicked off an in­ves­ti­ga­tion in­to “sky­rock­et­ing” drug prices in the Unit­ed States — a con­tentious is­sue that has sparked bi­par­ti­san furor — when he sent in­quiries to a dozen ma­jor drug­mak­ers seek­ing in­for­ma­tion on pric­ing prac­tices this Jan­u­ary. But it looks like two of his Re­pub­li­can col­leagues are not im­pressed with the probe, in­sin­u­at­ing that the De­mo­c­rat sen­a­tor is col­lect­ing “sen­si­tive in­for­ma­tion” to bring down phar­ma­ceu­ti­cal stock prices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER